He is Dr Steven Romano, the chief scientific officer at Mallinckrodt Pharmaceuticals, who has also held senior roles Pfizer and Eli Lilly
Silence Therapeutics PLC () has announced the appointment of an independent director from its new partner, New York-listed specialty pharma group Mallinckrodt (NYSE:MKN).
He is Dr Steven Romano, the chief scientific officer at Mallinckrodt Pharmaceuticals, who has also held senior roles and .
“With his executive responsibility for research and development, medical affairs and regulatory affairs functions at Mallinckrodt, Steve brings wealth of experience that is highly relevant to the current stages of development of Silence's assets," said Silence chief executive David Horn Solomon.
Earlier this month Silence agreed a partnership with Mallinckrodt to develop and commercialise gene silencing treatments for serious diseases worth an upfront US$20mln.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE